The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice

临床活性 PARP 抑制剂 AG014699 可改善心脏毒性，但不会增强阿霉素的疗效，尽管可以改善小鼠的肿瘤灌注和放射反应